Latest Breaking News On - Christopherj moreau - Page 3 : comparemela.com

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

30.11.2023 - VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) - Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to . Seite 1

Christopherj moreauChinese patent officeAlgernon pharmaceuticalsAlgernon pharmaceuticals registereda old chartLgernon pharmaceuticals registereda old kursLgernon pharmaceuticals registereda old aktie

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

British columbiaUnited kingdomChristopherj moreauCompany or algernonNo securities exchangeChinese patent officeNeither the canadian securities exchangeAlgernon pharmaceuticalsChristopherj moreauceoalgernon pharmaceuticals incAlgernon pharmaceuticals incCanadian securities exchangeTreating non alcoholicAlgernon neurosciencePharmaceuticals incMarket regulator

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U S Based Seyltx for USD $2M and a 20% Equity Position

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U S Based Seyltx for USD $2M and a 20% Equity Position
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

British columbiaUnited statesRheinland pfalzUnited kingdomChristopherj moreauNo securities exchangeMerck coAlgernon pharmaceuticals incCompany or algernonDrug administrationMarket researchAlgernon pharmaceuticalsCanadian securities exchangeBellus healthNeither the canadian securities exchangeAfferent pharmaceuticals

Algernon Pharmaceuticals Announces Grant of U S Patent for Repirinast in NAFLD and NASH

VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFUR.

United statesUnited kingdomBritish columbiaChristopherj moreauAlgernon pharmaceuticalsCanadian securities exchangeTrademark officeAlgernon pharmaceuticals incNeither the canadian securities exchangeCompany or algernonUnited states patentTreating non alcoholic steatohepatitisMitsubishi tanabe pharmaZhejiang ausun pharmaceuticalAlgernon neuroscienceMarket regulator

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study. AGN Neuro is the world’s first company to investigate DMT for the tre

British columbiaUnited kingdomCity ofChristopherj moreauEdmundj safraDavid nuttRick strassmanAlgernon pharmaceuticalsAlgernon pharmaceuticals incConstraint induced movement therapyCentre for human drug researchImperial college londonCompany phaseAlgernon neuroscienceSpirit moleculePsychedelic handbook